Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Targeted Intraoperative Radiotherapy for Early Breast Cancer—Reply

Targeted Intraoperative Radiotherapy for Early Breast Cancer—Reply Letters proportion score. The modification in using modified propor- Targeted Intraoperative Radiotherapy tion score is that mononuclear inflammatory cells that ex- for Early Breast Cancer press PD-L1 are counted in conjunction with the tumor cells, To the Editor We read with interest the report on the long-term and only tumor nests are scored for PD-L1 positivity, while the recurrence and survival outcomes after treatment with de- tumor-associated stroma is excluded. Scoring in our study for layed second-procedure targeted intraoperative radio- PD-L1 expression used the Dako 22C3 antibody. In contrast, the therapy (IORT) vs whole-breast radiotherapy by Vaidya et al. combined proportion score grades both tumor cells and mono- Since the publication of 5-year outcomes from the TARGIT-A nuclear inflammatory cells within tumor nests as well as tumor- trial, the oncology community has awaited long-term out- associated stroma. The Dako 22C3 test (Agilent Technolo- comes from the study to evaluate the utility of IORT for early gies) uses tumor proportion score and scores only reactive breast cancer. The recent publication of the delayed- tumor cells for PD-L1 in the commercially approved NSCLC treatment cohort of patients from the TARGIT-A trial has now indication. provided additional information. The study found that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Targeted Intraoperative Radiotherapy for Early Breast Cancer—Reply

Vaidya, Jayant Sharad; Bulsara, Max; Baum, Michael
JAMA Oncology , Volume 6 (10) – Oct 13, 2020
Download PDF
4 pages

Loading next page...
 
/lp/american-medical-association/targeted-intraoperative-radiotherapy-for-early-breast-cancer-reply-S01UOzdaRn

References (10)

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.2730
Publisher site
See Article on Publisher Site

Abstract

Letters proportion score. The modification in using modified propor- Targeted Intraoperative Radiotherapy tion score is that mononuclear inflammatory cells that ex- for Early Breast Cancer press PD-L1 are counted in conjunction with the tumor cells, To the Editor We read with interest the report on the long-term and only tumor nests are scored for PD-L1 positivity, while the recurrence and survival outcomes after treatment with de- tumor-associated stroma is excluded. Scoring in our study for layed second-procedure targeted intraoperative radio- PD-L1 expression used the Dako 22C3 antibody. In contrast, the therapy (IORT) vs whole-breast radiotherapy by Vaidya et al. combined proportion score grades both tumor cells and mono- Since the publication of 5-year outcomes from the TARGIT-A nuclear inflammatory cells within tumor nests as well as tumor- trial, the oncology community has awaited long-term out- associated stroma. The Dako 22C3 test (Agilent Technolo- comes from the study to evaluate the utility of IORT for early gies) uses tumor proportion score and scores only reactive breast cancer. The recent publication of the delayed- tumor cells for PD-L1 in the commercially approved NSCLC treatment cohort of patients from the TARGIT-A trial has now indication. provided additional information. The study found that

Journal

JAMA Oncology – American Medical Association

Published: Oct 13, 2020

There are no references for this article.